Conducted between June 2011 and March 2013 at 191 sites in 27 countries in Europe, North America, South America, Asia, and Australia this was a randomised, placebo-controlled trial designed to evaluate the efficacy and safety of 3mg liraglutide 'injected subcutaneously once daily, as an adjunct to a reduced-calorie diet and increased physical activity, for weight management in overweight or obese adults who did not have diabetes at baseline.' A total of 3,731 individuals participated in the trial, of whom 2,487 were assigned to lifestyle intervention plus liraglutide and 1,244 to lifestyle intervention with a placebo
Once you stop the medication, your gastric emptying rate returns to normal
Did your doctor prescribe Ozempic off-label for weight loss
2005 Aug;138(2):283-90
Starting on a low dose and increasing slowly gives your body time to adjust, making the side effects more manageable and treatment more tolerable overall
One mouse and one datapoint in vehicle group was omitted from analysis as they had insulin levels outside the assay range